A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
about
Complementary and alternative therapies for Down syndromeDonepezil for dementia due to Alzheimer's diseaseCurrent pharmacologic options for patients with Alzheimer's diseaseRational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysisSystematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase InhibitorsThe appropriate use of neuroimaging in the diagnostic work-up of dementia: an economic literature review and cost-effectiveness analysisStroke, dementia, and drug deliveryAlzheimer's disease: current pharmacotherapy in the context of patient and family needs.Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care PhysicianDonepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.Cost-effectiveness of drug therapies for Alzheimer's disease: A brief review.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.The developing utility of zebrafish models for cognitive enhancers researchDefining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.Functional outcomes of drug treatment in Alzheimer's disease: A systematic review and meta-analysis.Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease.Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver OutcomesMedication for Alzheimer's disease and associated fall hazard: a retrospective cohort study from the Alzheimer's Disease Neuroimaging Initiative.Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of ProgressionPersistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer diseaseCholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Advances in the pharmacotherapy of Alzheimer's disease.Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies.Effects on caregiver burden of a donepezil hydrochloride dosage increase to 10 mg/day in patients with Alzheimer's diseaseCholinergic enhancement increases the effects of voluntary attention but does not affect involuntary attention.Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohortThe safety and tolerability of donepezil in patients with Alzheimer's disease.Results, rhetoric, and randomized trials: the case of donepezil.Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilitiesDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsLong-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.
P2860
Q22252869-4B34CAD7-AB69-4329-AEEA-466272CC2FA6Q24244938-86864C4C-B356-41D0-A836-0647C2D1AFBDQ24800530-B452278F-9B69-4B84-9CFD-8C437EF7B63CQ24805169-E64FE900-AD7D-4D02-A0EE-F422E9C73223Q26863383-2818A6DE-8B90-4132-94C8-D77CB718B5D0Q27021201-BA3FB698-3046-4D6F-AA06-5D0A4595C271Q28166505-7EDD54C5-073C-4F85-ADEE-665AC60E0D7CQ30310930-788F39C2-16D3-428C-AF21-B60776C277BFQ30433785-447AFF93-8850-4185-AF20-3A45E172DC88Q30436664-D670D3A9-CE3A-4C40-9658-0136ACCC47A3Q30441091-D247DE74-2ACA-4DDA-810D-51C93F1D365CQ30443975-C6A0AE8A-9716-4993-96D1-C4AED129C8EAQ30457705-CB3A55FB-311C-4FCF-A4F2-39ECD4CF5E85Q31166026-B8A0E11A-D85C-46A8-89AC-C035662A6DDDQ33160127-1834352F-49F2-4023-A482-2786D7995DF0Q33165693-FE8D1E79-F70F-4410-8C2D-C9862010AB6AQ33274853-0DBD1F16-3E66-4BD2-916F-C6A0851163DCQ33599473-54343C8D-5564-4C17-B63D-439373D3F622Q33781824-8B86A367-B4BA-40E7-A137-8A65782E0C0CQ33792563-EECEDE42-E848-4F40-87FA-31B20CBAB9C3Q33801636-32E12FAB-3991-4F43-BB39-DFBF51EEA467Q33867858-59C02A36-7BDD-426D-AA23-EF0E9EE86A76Q33912750-123C8F8B-A9F1-46EE-8A02-C6393B00B61BQ33928316-B50EEFB9-8BBD-47FC-B016-CD0681F83195Q34011160-C2DF831E-495A-43A9-9E65-836542F2D89AQ34153726-54828AE8-9305-4882-8227-682FDF80A0E7Q34156798-D7D730BC-D153-4A68-9B95-579C49B13AB9Q34230445-876EAD60-E595-454D-8141-CB40D357F00DQ34300082-4F02E8F9-1F01-4D4B-9148-8B9605F2DABDQ34408888-2BC61063-7C56-49AD-A627-47C16421B434Q34418562-CD15AAA3-35F9-4B3E-8DF3-D337A4833D2EQ34466802-44A170F9-5140-4C69-BDBE-23D464956B69Q34552035-86BE571B-A18F-4D72-8B7C-B2A8531323BBQ34594786-B69F735C-687B-4967-9754-A3C2689CCC43Q34629649-8AD629F6-E3ED-4D6D-A0A9-6135BFE6DF49Q34648742-960049D8-4B50-412C-A614-E49695EDAD06Q34789455-8F5909E1-EBF4-4893-A502-8429F489B753Q34965949-E74067F5-74E5-41C7-A8FA-DF2A02306CFBQ35006354-A985EF5A-D8B5-4601-B30F-A3CC34DA9226Q35112092-7A8A3581-84B0-429F-A7C5-243DFEB70E07
P2860
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@ast
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@en
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@nl
type
label
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@ast
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@en
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@nl
prefLabel
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@ast
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@en
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@nl
P2093
P356
P1433
P1476
A 1-year, placebo-controlled p ...... y of donepezil in AD patients.
@en
P2093
"312" Study Group
C A Perdomo
J C Morris
S L Rogers
P304
P356
10.1212/WNL.57.3.481
P407
P577
2001-08-01T00:00:00Z